Figures computed from official regulatory filings — .
Analysttarget 13.67 USD (+45%) · consensus 4.33/5 · 2 buy · 1 hold · 0 sell
Ownershipinsiders 16.8% · institutions 57.67% · short 5.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Atara Biotherapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
23 buys675 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Cherry Brian N | Buy | $1M | conv 69First in 12mo |
| SEC |
| Nguyen AnhCo | Sell | $40.9K | Unusual size | SEC |
| Redmile Group, LLCtrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Redmile Group, LLCtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Redmile Group, LLCtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Redmile Group, LLCtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Redmile Group, LLCtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cherry Brian N | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fust Matthew K | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ciongoli Gregory Austin | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| HEIDEN WILLIAM Ktrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Grant-Huerta Yanina | Sell | $22K | SEC |
| Nguyen AnhCo | Sell | $47.8K | Unusual size | SEC |
| Panacea Innovation Ltd | Sell | $3.2M | SEC |
| EcoR1 Capital, LLCtrack record | Buy | $4.7M | conv 34 | SEC |
| Panacea Innovation Ltd | Other | $26.2 | SEC |
| Panacea Innovation Ltd | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Panacea Innovation Ltd | ExerciseD (derivative) | $1.7M | SEC |
| Grant-Huerta Yanina | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nguyen AnhCo | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nguyen AnhCo | Sell | $294.6 | SEC |
| Grant-Huerta Yanina | Sell | $8.1K | SEC |
| Grant-Huerta Yanina | Sell | $121.9 | SEC |
| Nguyen AnhCo | Sell | $6.6K | SEC |
| Grant-Huerta Yanina | Sell | $1.9K | SEC |